A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Sponsor: Janssen Research & Development, LLC
Terminated
The study crossed the prospective futility boundary of primary endpoint
Other terminated trials from Janssen Research & Development, LLC
- Multiple Myeloma · Phase PHASE2 · Oct 2025
- Depressive Disorder, Major · May 2025
- Anhedonia · Phase PHASE3 · Apr 2025
- Anhedonia · Phase PHASE3 · Apr 2025
- Dengue · Phase PHASE2 · Jun 2024
More terminations from Janssen Research & Development, LLC
Other Metastatic Colorectal Cancer trials with similar outcome
Listed as NCT01767857, this PHASE3 trial focuses on Metastatic Colorectal Cancer and remains terminated or withdrawn. Sponsored by Janssen Research & Development, LLC, it has been updated 11 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jul 2017 — Sep 2017 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .